Despite many advantages of CAPD in maintaining hemodynamic stability, approximately 50% -60% of CAPD patients have hypertension and require antihypertensive treatment. ACE inhibitors and betablockers are the preferred first-line antihypertensive drugs in these patients, but some patients may require additionallong-acting calcium antagonists to enhance antihypertensive effects. Despite antihypertensive treatment, many patients often fail to maintain BP within optimal ranges, and this fact may contribute to the high incidences of cardiovascular morbidity an d mortality. Vigilance is clearly desirable by the patient and the physician to maintain BP within target ranges most of the time. Because dialysis patients also have many other cardiovascular risk factors, the strategy to decrease cardiovascular mortality should be a combined effort targeting all potential risk factors at the same time.
United States Department of Health and Human Services, Public Health Service, National Institutes of Health.USRDS 1998 Annual Data Report.Bethesda, MD: United States Renal Data System; 1998.
2.
LameireN., BernaertP., LambertM.C., VijtD.Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis.Kidney Int.1994; 46(Suppl 48): S31–8.
3.
Department of Health and Human Services.1997 Annual Report. ESRD Core Indicators Project. December 1997.
4.
Department of Health and Human Services.1996 Annual Report. ESRD Core Indicators Project. January 1997.
5.
SaldanhaL., WeilerE.W.J., GonickH.C.Effect of continuous ambulatory peritoneal dialysis on blood pressure control.Am J Kidney Dis.1993; 21: 184–8.
6.
CheighJ.S.The role of ambulatory blood pressure monitoring in patients with end-stage renal disease.Semin Dial.1998; 11: 148–50.
7.
RodbyR.A., VoneshE.F., KorbetS.M.Blood pressures in hemodialysis and peritoneal dialysis using ambulatory blood pressure monitoring.Am J Kidney Dis.1994; 23: 401–11.
8.
CanzianiM.E., NetoM.C., SaragocaM.A., CassiolatoJ.L., RamosO.L., AjzenH.Hemodialysis versus continuous ambulatory peritoneal dialysis: Effects on the heart.Artif Organs.1995; 19: 241–4.
9.
CheighJ.S., SerurD., PaguiriganM., StenzelK.H., RubinA.How well is hypertension controlled in CAPD patients? In: KhannaR., ed. Advances in Peritoneal Dialysis.Toronto: Peritoneal Dialysis Publications, 1994; 10: 55–9.
10.
EniaG.Impact of hypertension in CAPD patients.Contrib Nephrol.1996; 119: 147–51.
11.
ZazgornikJ., BiesenbachG., ForstenlahnerM., StummvollK.Profile of antihypertensive drugs in hypertensive patients on renal replacement therapy.Clin Nephrol.1997; 48: 337–40.
12.
TomitaJ., KimuraG., InoueT., InenagaT., SanaiT., KawanoY.Role of systolic blood pressure in determining prognosis of hemodialyzed patients.Am J Kidney Dis.1995; 25: 405–12.
13.
CharraB., CalemardE., RuffetM., ChazotC., TerratJ.C., VanelT.Survival as an index of adequacy of dialysis.Kidney Int.1992; 41: 1286–91.
14.
United States Renal Data System.USRDS 1992 Annual Report: VI. Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients.Am J Kidney Dis.1992; 2: 32–8.
15.
LowrieE.G., HuangN.L., LewN.L., LiuY.The relative contribution of measured variables to death risk among hemodialysis patients. In: FriedmanE.A., ed. Death on Dialysis: Preventable or Inevitable?Dordrecht: Kluwer Academic Publishers; 1994: 121–41.
16.
DurantiE., ImperialiP., SasdelliM.Is hypertension a mortality risk factor in dialysis?Kidney Int.1996; 49: 173–4.
17.
FoleyR.N., ParfreyP., HarnettJ., KentG., MurrayD., BarréP.Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease.Kidney Int.1996; 49: 1379–85.
18.
ZagerP.G., NikolicJ., BrownR., CampbellM., HuntW., PetersonD.“U” curve association of blood pressure and mortality in hemodialysis patients.Kidney Int.1998; 54: 561–9.
19.
CannellaG., PaolettiE., DelfinoR., PelosoG., MolinariS., TraversoG.Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy.1993; 44: 881–6.
20.
National Institutes of Health.The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure.Arch Intern Med.1997; 157: 2413–46.
21.
HanssonL., ZanchettiA., CarruthersG., DahlofB., ElmfeldtD., JuliusS.Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial.Lancet.1998; 351: 1755–62.
22.
ManolioT., CutlerJ., FurbegC., PsatyB., WheltonP., ApplegateW.B.Trends in pharmacologic management of hypertension in the United States.Arch Intern Med.1995; 155: 829–37.
23.
PsatyB., SmithN., SiscovickD., KoepsellT., WeissN., HeckbertS.Health outcomes associated with antihypertensive therapies used as first line agents.JAMA.1997; 277: 739–45.
24.
AldermanM., CohenH., RoqueR., MadhavenS.Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients.Lancet.1997; 349: 594–8.
25.
YusufS., HeldP., FurbergC.Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction trial and other recent studies.Am J Cardiol.1991; 67: 1295–7.
26.
PsatyB.M., HeckbertS.R., KoepsellT.D.The risk of myocardial infarction associated with antihypertensive drug therapies.JAMA.1995; 274: 620–5.
27.
FurbergC.D., PsatyB.M., MeyerJ.V.Nifedipine: Doserelated increase in mortality in patients with coronary heart disease.Circulation.1995; 92: 1326–31.
28.
EstacioR., JeffersB., HiattW., BiggerstaffS., GiffordN., SchrierR.The effect of Nisoldipine as compared with Enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension.N Engl J Med.1998; 338: 645–82.
29.
WongK.C., WooK.S., LamW.K., LiK.T., LaiK.N., NichollsM.G.A comparison of the effect of enalapril and metoprolol on renal function, potassium balance, lipid profile, cardiac function, exercise tolerance and quality of life in hypertensive dialysis patients.Int J Artif Organs.1995; 18: 757–62.
30.
FavazzaA., MontanaroD., MessaP., AntonucciF., GropuzzoM., MioniG.Peritoneal clearances in hypertensive CAPD patients after oral administration of clonidine, enalapril and nifedipine.Perit Dial Int.1992; 12: 287–91.
31.
SempleP.F.Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors.Br Med J.1988; 296: 86–8.
32.
PedroP., GehrT.W.B., SicaD., FakhryI., FarthingD.The pharmacokinetics and pharmacodynamics of Losartan in CAPD patients [Abstract].Perit Dial Int.1998; 18(Suppl 1): S53.
33.
BurtV.L., WheltonP., RocellaE.J.Prevalence of hypertension in the U.S. adult population. Results from the Third National Health and Nutrition Examination Study.Hypertension.1995; 25: 305–13.
34.
BurtV.L., CutlerJ.A., HigginsM.Trends in the prevalence, awareness, treatment, and control of hypertension in the adult U.S. population. Data from the Health Examination Studies, 1960 to 1961.Hypertension.1995; 26: 60–9.
35.
VelasquezM.T., LewS.Q., AlbertiniV., MishkinG., BoschJ.Control of hypertension is better during hemodialysis than during continuous ambulatory peritoneal dialysis in ESRD patients.Clin Nephrol.1997; 48: 341–5.
36.
CheighJ.S., MiliteC., SullivanJ., RubinA., StenzelK.Hypertension is not adequately controlled in hemodialysis patients.Am J Kidney Dis.1992; 19: 453–9.
37.
N akayamaM., KawaguchiY., YokoyamaK., KuboH., MiuraY., WatanabeS.Antihypertensive effect of low Na concentration (120 mEq/L) solution for CAPD patients.Clin Nephrol.1994; 41: 357–63.
